ADAPTIVE AND INNATE IMMUNE RESPONSES
TRIGGERED TO NEUTRALIZE GASTRIN HORMONES
AS A THERAPY FOR GI CANCERS

COMPANY


TYG Oncology Ltd. is a biotech start-up company founded in 2013, that develops novel therapeutic vaccines to treat gastric cancers. TYG's vaccines are based on a unique, proprietary technology platform. They are directed against major gastric cancers that currently cannot be cured. Lead candidate TYG100 targets pancreatic cancer utilizing the break-through delivery technology paired with the extensive knowledge and clinical proof of the target gastrin, a natural gastric hormone, being the main nutrition for pancreatic - as well as other forms of gastric cancer cells. TYG Oncology Ltd. was founded by four experienced, senior pharma professionals with top-level research & development, clinical, management, and finance backgrounds. The privately held company is based in the UK.

Commercialising and capitalising on the R&D advances of G17DT, TYG100 uses a novel, activation system that triggers adaptive and innate responses that have produced superior preclinical results and approximately 100% responders:

  • Safe and well-tolerated with less local reactivity than G17DT
  • Personalized dosing in the convenience of the patient home
  • Fast track strategy designed to enable early regulatory approval
  • Our Orphan Drug strategy requires less funding

[Sleeker_special_clear]